Abstract
Since the introduction of chemotherapy in cancer therapy, development of resistance to every new therapeutic has been the universal experience. The growing understanding of cancer genomics, cancer-associated signal transduction pathways, and key protein drivers of cancer has enabled cancer biologists and medicinal chemists to develop targeted molecules to interfere with these pathways to tackle drug resistant cancers. However, to the dismay of oncologists, the clinical use of many of these tools has once again brought to the forefront the inevitable challenge of drug resistance. It is now understood that cancer resistance to different therapies involves multiple challenges that encompass the cancer cell itself as well as host physiology. This review presents small molecule inhibitors and peptides as two therapeutic approaches in anti-cancer drug development. Resistance to selected samples of these novel therapies is described in the context of cell autonomous resistance, the contributions of the tumor microenvironment, and germ line factors. For each approach, advantages and disadvantages are discussed on how to better overcome the inevitable challenge of resistance in cancer treatment.
Keywords: Anti-cancer peptides, drug resistance, small molecule inhibitors, targeted cancer therapy.
Current Medicinal Chemistry
Title:Tumor-Targeting Peptides and Small Molecules as Anti-Cancer Agents to Overcome Drug Resistance
Volume: 21 Issue: 14
Author(s): Ehsan Sarafraz-Yazdi, Matthew R. Pincus and Josef Michl
Affiliation:
Keywords: Anti-cancer peptides, drug resistance, small molecule inhibitors, targeted cancer therapy.
Abstract: Since the introduction of chemotherapy in cancer therapy, development of resistance to every new therapeutic has been the universal experience. The growing understanding of cancer genomics, cancer-associated signal transduction pathways, and key protein drivers of cancer has enabled cancer biologists and medicinal chemists to develop targeted molecules to interfere with these pathways to tackle drug resistant cancers. However, to the dismay of oncologists, the clinical use of many of these tools has once again brought to the forefront the inevitable challenge of drug resistance. It is now understood that cancer resistance to different therapies involves multiple challenges that encompass the cancer cell itself as well as host physiology. This review presents small molecule inhibitors and peptides as two therapeutic approaches in anti-cancer drug development. Resistance to selected samples of these novel therapies is described in the context of cell autonomous resistance, the contributions of the tumor microenvironment, and germ line factors. For each approach, advantages and disadvantages are discussed on how to better overcome the inevitable challenge of resistance in cancer treatment.
Export Options
About this article
Cite this article as:
Sarafraz-Yazdi Ehsan, Pincus R. Matthew and Michl Josef, Tumor-Targeting Peptides and Small Molecules as Anti-Cancer Agents to Overcome Drug Resistance, Current Medicinal Chemistry 2014; 21 (14) . https://dx.doi.org/10.2174/09298673113209990223
DOI https://dx.doi.org/10.2174/09298673113209990223 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PPARγ and Its Ligands: Potential Antitumor Agents in the Digestive System
Current Stem Cell Research & Therapy Epigenetic Changes Induced by Green Tea Catechins a re Associated with Prostate Cancer
Current Molecular Medicine Activin Receptor-Like Kinase 1: a Novel Anti-angiogenesis Target from TGF-β Family
Mini-Reviews in Medicinal Chemistry Botulinum Toxin: Pharmacology and Clinical Developments: A Literature Review
Medicinal Chemistry Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Current Neuropharmacology Recent Approaches in Chemoprevention of Prostate Cancer
Current Cancer Drug Targets Multiple Myeloma and the Immune Microenvironment
Current Cancer Drug Targets The Therapeutic Potential of Gallium-Based Complexes in Anti-Tumor Drug Design
Letters in Drug Design & Discovery Recent Advances in Delivery of Cytokines, Growth Factors, and Molecules of Therapeutic Interest from Hyaluronan-based Hydrogels
Current Tissue Engineering (Discontinued) Modulation of the Ceramide Level, A Novel Therapeutic Concept
Current Drug Targets Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
Current Medicinal Chemistry Vesicle Trafficking, Autophagy and Nanoparticles: A Brief Review
Current Nanomedicine Sulfotransferase 1A1 as a Biomarker for Susceptibility to Carcinogenesis: From Molecular Genetics to the Role of Dietary Flavonoids
Current Drug Metabolism Lanthanum, Gallium and their Impact on Oxidative Stress
Current Medicinal Chemistry Collagen: The Oldest Scaffold for Tissue Regeneration
Current Tissue Engineering (Discontinued) An Update on the Systemic Therapy of Malignant Salivary Gland Cancers: Role of Chemotherapy and Molecular Targeted Agents
Current Medicinal Chemistry - Anti-Cancer Agents Bone Morphogenetic Protein-Smad Pathway as Drug Targets for Osteoporosis and Cancer Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Bone Metastases Radiopharmaceuticals: An Overview
Current Radiopharmaceuticals Recent Advances in Flavivirus Antiviral Drug Discovery and Vaccine Development
Recent Patents on Anti-Infective Drug Discovery